Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BPhytohealth Corp. 〉PHN131 (Treat moderate to severe pain)

PHN131 (Treat moderate to severe pain)

PHN131 (Treat moderate to severe pain)

A commercially available narcotic drug with new route of administration (from injection to oral administration)for treating Moderated to Severe Pain. The PHN131's.pivotal clinical trialhas been completed and the data unblended to demonstrate positive resu

Request for Collaboration
Overview
Advantages of the product
  • New oral formulation derived from an approved analgesic injectable - Nalbuphine
  • Patented technology inhibits first-pass metabolism to improve oral bioavailability
  • Potency equivalent to Morphine per milligram basis
  • Low physical dependence and addiction
  • Convenience with oral administration
  • Ceiling effect for side-effect of respiratory depression
Notable achievements
  • Co-development with the National Defense Education and Research Foundation
  • 【PHN131】was awarded the 2009 Taipei Biotech Award in Industry Cooperation category 
  • 【PHN131】was awarded the 7th National Innovation Award
  • The PHN131's.pivotal clinical trial had been completed on March 2016 and the data unblended to demonstrate positive result.
Application
For treating Moderated to Severe Pain
Patent Portfolio
 
The US, China, Canada, Japan and Taiwan Patents have been approved.
Collaboration Options
  • Licensing
  • Co-development
People who like this also like
  • GLP LaboratoriesGLP Laboratories
  • TLC590TLC590
  • PDL(Precision Dimension Laser)PDL(Precision Dimension Laser)
  • PHN013 (Orphan drug;ITP)PHN013 (Orphan drug;ITP)
  • cGMP Complied Pilot FacilitycGMP Complied Pilot Facility
  • Advanced technology in material scienceAdvanced technology in material science
  • PeptidePeptide
  • JHL1152 Ipilimumab BiosimilarJHL1152 Ipilimumab Biosimilar
  • FB317FB317
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)